DOI: https://doi.org/10.22141/2308-2097.53.2.2019.168985

Correlation of immunological and biochemical indicators in patients with chronic diffuse liver diseases depending on the etiological factors of steatosis and liver fibrosis

V.I. Didenko, I.A. Klenina, O.M. Tatarchuk, O.P. Petishko

Abstract


Background. The purpose was to determine the relationship of immunity indicators with the main biochemical parameters in patients with chronic diffuse liver diseases, depending on the etiological factors of steatosis and liver fibrosis. Materials and methods. We examined 120 patients with chronic diffuse liver diseases. They were divided according to the etiological factor of steatosis and liver fibrosis: group I — 24 patients with non-alcoholic fatty liver disease (NAFLD), group ІІ — 37 persons with non-alcoholic steatohepatitis (NASH); group III — 21 people with chronic viral hepatitis associated with C virus; group IV consisted of 18 patients with alcoholic liver disease (ALD), group V — 20 individuals with toxic drug-induced hepatitis (TDIH). To characterize the metabolism of lipids in serum, total cholesterol, low-density lipoproteins were determined. Serum lipids were evaluated by determi­ning the content of triacylglycerols (TG), high-density lipoproteins (HDL), atherogenic index (AI) was calculated. The processes of fibrosis were assessed by the content of hydroxyproline free (HPf) and hydroxyproline protein-bound, hexosamine and hyaluronic acid. The presence of endogenous intoxication was determined by the content of medium molecular peptides (MMP). The content of cellular immunity parameters, the level of circulating immune complexes (CIC), interleukins (IL) 6, 10, tumor necrosis factor α (TNF-α), insulin and HOMA-IR were determined. A correlation analysis was made of biochemical and immunological parameters in the examined patients. Results. The data obtained in patients with chronic diffuse liver disease show active inflammatory processes. This is indicated by increased levels of pro-inflammatory cytokines (IL-6 and TNF-α), MMP. IL-6 overproduction is accompanied by a decrease in total phospholipids (PL) in the blood serum of patients with NAFLD, NASH and TDIH — an average correlation was found between IL-6 and PL (r = –0.44, p < 0.05; r = –0.45, p < 0.01; r = –0.44, p < 0.05, respectively). In patients with NASH, an increase in CIC level is accompanied by impaired lipid metabolism, namely, an increase in serum AI — CIC/AI (r = +0.39, p < 0.05) and a decrease in the anti-atherogenic fraction of CIC/HDL (r = –0.36, p < 0.05), as evidenced by the established average correlation. It was shown that an increase in the level of TNF-α in parallel is associated with phenomenon of endotoxemia in patients with NAFLD, as evidenced by the average correlation between TNF-α and MMP (r = +0.54, p < 0.05). An increase in T-cytotoxic lymphocytes was accompanied by a decrease in serum HDL and TG, as evidenced by an average correlation: between CD8+ lymphocytes and HDL (r = –0.53, p < 0.05) and TG (r = –0.53, p < 0.05), respectively, in patients with ALD. In addition, in this group of patients, there was no activation of IL-10 production in response to inflammation, which was associated with a decrease in the degradation of mature insoluble collagens, as indicated by the average correlation between IL-10 and HPf (r = –0.64, p < 0.01). Conclusions. The data obtained indicate the relationship between immunological and biochemical para­meters in patients with chronic diffuse liver diseases depending on the etiological factors of steatosis and liver fibrosis.


Keywords


chronic diffuse liver diseases; lipids; hydroxyproline; immunity; cytokines

References


Chen R, Han S, Dong D, et al. Serum fatty acid profiles and potential biomarkers of ankylosing spondylitis determined by gas chromatography–mass spectrometry and multivariate statistical analysis Biomed Chromatogr. 2015 Apr;29(4):604-11. doi: 10.1002/bmc.3321.

Wang DC, Sun CH, Liu LY, et al. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiol Aging. 2012 Jun;33(6):1057-66. doi: 10.1016/j.neurobiolaging.2010.09.013.

Cao H, Hotamisligil GS. Fatty acid c16: 1n7-palmitoleate a lipokine and biomarker for metabolic status. US Patent, Application number 13/062,527, Publication number US20110213032A1. 2011.

Jiang M, Chen T, Feng H, et al. Serum metabolic signatures of four types of human arthritis. J Proteome Res. 2013 Aug 2;12(8):3769-79. doi: 10.1021/pr400415a.

Perez-Cornago A, Brennan L, Ibero-Baraibar I, et al. Metabolomics identifies changes in fatty acid and amino acid profiles in serum of overweight older adults following a weight loss intervention. J Physiol Biochem. 2014 Jun;70(2):593-602. doi: 10.1007/s13105-013-0311-2.

Lien SK, Kvitvang HF, Bruheim P. Utilization of a deuterated derivatization agent to synthesize internal standards for gas chromatography-tandem mass spectrometry quantification of silylated metabolites. J Chromatogr A. 2012 Jul 20;1247:118-24. doi: 10.1016/j.chroma.2012.05.053.

Stigter EC, Letsiou S, vd Broek NJ, et al. Development and validation of a quantitative LC-tandem MS assay for hexadeca-4,7,10,13-tetraenoic acid in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Apr 15;925:16-9. doi: 10.1016/j.jchromb.2013.01.012.

Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014 May 15;15(5):8713-42. doi: 10.3390/ijms15058713.

Didenko VI, Oshmyanskaya NYu, Klenina IA. Morphological and biochemical evaluation of progression of chronic hepatitis associated with C virus. Gastroenterologia. 2014;(52):37-41. doi: 10.22141/2308-2097.2.52.2014.81949. (in Russian).

Didenko VI. Recent advances in the assessment of hepatic steatosis. Gastroenterologia. 2015;(57):94-100. doi: 10.22141/2308-2097.3.57.2015.81530. (in Russian).

Ichino N, Osakabe K, Nishikawa T, et al. A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol. 2010 Oct 14;16(38):4809-16. doi: 10.3748/wjg.v16.i38.4809.

Gold EW. The quantitative spectrophotometric estimation of total sulfated glycosaminoglican levels. Biochim Biophys Acta. 1981 Apr 3;673(4):408-15.

Aldasheva ZhA. Cytokines in the diagnosis of non-alcoholic hepatic steatosis. Cytokines and inflammation. 2013;12(3):95-99. (in Russian).

Litvinova LS, Kiriyenkova YeV, Aksyonova NN, Gazatova ND, Zatolokin PA. Features of cellular immunity and cytokine repertoire in patients with metabolic syndrome. Bulletin of Siberian Medicine. 2012;11(3):53-57. (in Russian).

Tsukanov VV, Kasparov EV, Tonkikh YuL, Vasyutin AV. New aspects of non-alcoholic fatty liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2015;25(4):34-38. (in Russian).

Głowacki MK, Cieśla A, Cibor D, et al. Selected apoptotic markers in serum of patients with chronic viral hepatitis C. Przegl Lek. 2014;71(7):369-73.

Zhong W, Li Q, Xie G, et al. Dietary fat sources differentially modulate intestinal barrier and hepatic inflammation in alcohol-induced liver injury in rats. Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(12):G919-32. doi: 10.1152/ajpgi.00226.2013.

Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013 Aug 22;369(8):754-62. doi: 10.1056/NEJMct1209614.

Babinets LC, Kitsay KYu. Clinical and pathogenetic aspects of chronic pancreatitis of biliary genesis and obesity. Gastroenterologia. 2016;(59):86-92. doi: 10.22141/2308-2097.1.59.2016.74538. (in Ukrainian).

Glushhenko SV. Optymizacija diagnostyky ta likuvannja nealkogol'nogo steatogepatytu u hvoryh na cukrovyj diabet 2 typu shljahom vyvchennja markeriv mitohondrial'noi' dysfunkcii'. Diss. kand. med. nauk [Optimization of diagnosis and treatment of non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus by studying markers of mitochondrial dysfunction. PhD diss.]. Kharkiv; 2015. 18 p. (in Ukrainian).

Tatarchuk OM, Didenko VI, Melanich CL, Kudryavtseva VE. Immunological reactivity in patients with chronic diffuse liver disease. Gastroenterologia. 2018;(52):222-226. doi: 10.22141/2308-2097.52.4.2018.154142. (in Ukrainian).




Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта